Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072302 · ClinicalTrials.gov registry record · Phase 1
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT04072302: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT04072302 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072302, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.
Primary Outcome
The number of subjects that became infected with malaria at each dose
Interventions
- DRUG Placebo
- DRUG KAF156
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
What the finished NCT04072302 record still lists
NCT04072302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04072302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04072302 about?
NCT04072302 is a clinical study titled "Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model". This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.
What is the current status of trial NCT04072302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2014-09-15. Estimated completion is 2017-11-29.
What interventions are being tested in trial NCT04072302?
The interventions under investigation include: Placebo (DRUG), KAF156 (DRUG).
Who is sponsoring clinical trial NCT04072302?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04072302's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI